MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Makes New $1.40 Million Investment in Insulet Corporation (NASDAQ:PODD)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH acquired a new stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 5,337 shares of the medical instruments supplier's stock, valued at approximately $1,402,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Empowered Funds LLC lifted its stake in shares of Insulet by 357.4% in the 4th quarter. Empowered Funds LLC now owns 4,327 shares of the medical instruments supplier's stock worth $1,130,000 after acquiring an additional 3,381 shares during the period. Asset Management One Co. Ltd. increased its position in shares of Insulet by 2.3% in the fourth quarter. Asset Management One Co. Ltd. now owns 26,766 shares of the medical instruments supplier's stock worth $7,096,000 after acquiring an additional 605 shares in the last quarter. Vontobel Holding Ltd. raised its stake in Insulet by 4.3% during the 4th quarter. Vontobel Holding Ltd. now owns 2,423 shares of the medical instruments supplier's stock valued at $633,000 after purchasing an additional 100 shares during the period. Banque Pictet & Cie SA acquired a new stake in Insulet during the 4th quarter worth about $287,000. Finally, Valeo Financial Advisors LLC acquired a new position in Insulet in the 4th quarter valued at approximately $208,000.

Insulet Stock Down 0.7%

Insulet stock traded down $2.20 during mid-day trading on Tuesday, reaching $304.39. The company's stock had a trading volume of 591,849 shares, compared to its average volume of 711,970. The company has a debt-to-equity ratio of 1.21, a quick ratio of 3.63 and a current ratio of 4.47. Insulet Corporation has a 12 month low of $173.00 and a 12 month high of $329.33. The business's 50 day simple moving average is $288.34 and its 200 day simple moving average is $275.34. The company has a market capitalization of $21.42 billion, a price-to-earnings ratio of 84.69, a price-to-earnings-growth ratio of 2.73 and a beta of 1.37.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.21. The company had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. Insulet had a return on equity of 22.25% and a net margin of 18.29%. Insulet's revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.73 EPS. As a group, research analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on PODD. Citigroup reissued a "buy" rating and issued a $380.00 price target (up previously from $320.00) on shares of Insulet in a research report on Thursday, May 22nd. Raymond James Financial restated an "outperform" rating and issued a $360.00 price target (up from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Wells Fargo & Company set a $322.00 price target on Insulet in a report on Monday, April 28th. Royal Bank Of Canada initiated coverage on shares of Insulet in a research report on Thursday, March 6th. They set an "outperform" rating and a $340.00 target price on the stock. Finally, Wolfe Research upgraded Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective for the company in a research report on Tuesday, May 13th. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, Insulet presently has an average rating of "Moderate Buy" and an average price target of $321.00.

Insiders Place Their Bets

In other news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. The trade was a 36.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the transaction, the senior vice president now directly owns 23,180 shares of the company's stock, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.